CorMedix Inc. filed soliciting material under Schedule 14A (DFAN14A) on November 16, 2026, in connection with its proposed acquisition of substantially all of the assets of Heron Therapeutics and its third quarter 2026 earnings disclosures.

Key Highlights

  • Q3 2026 revenue: CorMedix reported consolidated revenue of $54.5 million, described as above consensus, according to the filing.
  • Adjusted EBITDA: The company reported adjusted EBITDA of $3.1 million for the third quarter, with full year 2026 adjusted EBITDA guidance narrowed to $130 million to $140 million.
  • Cash position: The company ended the quarter with $355 million in cash.
  • Full year 2026 revenue guidance reaffirmed: CorMedix reaffirmed full year 2026 revenue guidance in a range of $325 million to $345 million.
  • Heron Therapeutics acquisition: CorMedix entered a definitive agreement to acquire substantially all of Heron Therapeutics' assets, with closing anticipated in the first quarter of 2027, subject to Heron stockholder approval, regulatory clearance, and other customary closing conditions.
  • Contingent consideration: Up to $55 million of the transaction consideration is contingent on ZYNRELEF achieving net sales milestones in calendar year 2028.
  • Estimated cost synergies: The company disclosed estimated operating cost synergies of $45 million to $60 million on an annualized run rate basis, expected to be achieved by the end of 2027.

CorMedix Q3 2026 Results and Heron Therapeutics Asset Acquisition Details

According to the filing, CorMedix (NASDAQ:CRMD) reported Q3 2026 consolidated revenue of $54.5 million, above consensus, and adjusted EBITDA of $3.1 million. The company ended the quarter with $355 million in cash. Management reaffirmed full year 2026 revenue guidance of $325 million to $345 million and narrowed adjusted EBITDA guidance to the top end of the prior range, at $130 million to $140 million.

The filing disclosed that CorMedix entered a definitive agreement to acquire substantially all of the assets of Heron Therapeutics, including commercial and pipeline assets. The Heron portfolio, which the filing states generated approximately $150 million of net product revenue over the trailing 12 months, is expected to contribute approximately $125 million to $150 million of revenue for pro forma 2027. The company characterized this as "roughly doubling the revenue base for our non-DefenCath portfolio." The transaction includes up to $55 million in contingent consideration tied to ZYNRELEF net sales milestones in calendar year 2028, as well as royalty-based contingent payments for CINVANTI, SUSTOL, and products launched under a multiproduct development agreement. The transaction is described as expected to be "immediately accretive to earnings and free cash flow upon closing."

On the reimbursement environment, the filing noted that the Centers for Medicare and Medicaid Services (CMS) established a post-TDAPA add-on of $8.32 for the first quarter of 2027 and finalized a new quarterly reset methodology. The company disclosed that it "currently expects the add-on in each quarter of 2027 to exceed the current $2.37" and estimates "the full year average to be at least double that current rate," while noting the new mechanism will result in overall average reimbursement lower than $8.32 over the course of the year. The filing additionally noted that the FDA accepted the sNDA for REZZAYO for the prophylaxis of invasive fungal disease with priority review.

What Was Disclosed

This DFAN14A filing presents CorMedix's Q3 2026 earnings results, full year 2026 guidance, details of the proposed Heron Therapeutics asset acquisition including contingent consideration, estimated synergies, and an update on the 2027 DefenCath reimbursement outlook under new CMS quarterly reset methodology.